INCY News and Press, Incyte Corporation From 09/14/20

Eli Lilly (NYSE: LLY ) announces positive preliminary results from an NIAID-sponsored clinical trial, ACTT-2 , evaluating the combination of baricitinib and Gilead Sciences' (NASDAQ: GILD ) remdesivir in more than 1,000 hospitalized COVID-19 patients. More news on: Eli Lilly and Com...

INDIANAPOLIS , Sept. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of ...

Massachusetts General Cancer Center awarded $100,000 to launch a patient-centered mobile intervention app for people with chronic graft-versus-host disease (GVHD) Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuit...

Calithera signals terminating partnership with Incyte Calithera Biosciences Inc. ( CALA ) reported that it has sent a written intimation to Incyte ( INCY ) terminating their collaboration and licensing agreement. The termination will be effective from September 30. The companies had entere...

Calithera Biosciences (NASDAQ: CALA ) discloses that it has delivered written notice to Incyte (NASDAQ: INCY ) terminating their January 2017 collaboration and license agreement effective September 30. More news on: Calithera Biosciences, Inc., Incyte Corporation, Healthcare stocks...

— Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14) — Tabrecta is the fourth molecule discovered by Incyte scientists to be approved ...

Oncolytics Biotech (NASDAQ: ONCY ) has dosed first patient in Phase 2 IRENE study of Company's pelareorep in combination with Incyte's (NASDAQ: INCY ) anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in unresectable locally advanced or metastatic triple-negative breast ...

MorphoSys AG (NASDAQ: MOR ) and collaborator/licensee Incyte (NASDAQ: INCY ) announce that Monjuvi (tafasitamab-cxix) has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-cell lymphomas. More news on: MorphoSys AG, Incyt...

MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that Monjuvi ® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer N...

Image source: The Motley Fool. Incyte Corp   (NASDAQ: INCY) Q2 2020 Earnings Call Aug 4, 2020 , 8:00 a.m. ET Operator Continue reading